Skip to main content

Eli Lilly and Company Japan revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Japan revenue at Eli Lilly and Company came to $648.0M for the quarter to 30 Sep 2026, up 16.8% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$439.0MDec 2023$363.9MMar 2024$462.7MJun 2024$429.1MSep 2024$559.2MDec 2024$402.0MMar 2025$521.0MJun 2025$555.0MSep 2025$654.0MDec 2025$571.0MMar 2026$628.0MJun 2026$648.0MSep 2026
Eli Lilly and Company Japan revenue, every reported period
Period endingJapan revenueChange on a yearFiled
30 Sep 2026$648.0Mup 16.8%29 Oct 2026
30 Jun 2026$628.0Mup 20.5%5 Aug 2026
31 Mar 2026$571.0Mup 42.0%30 Apr 2026
31 Dec 2025$654.0Mup 17.0%12 Feb 2026
30 Sep 2025$555.0Mup 29.3%30 Oct 2025
30 Jun 2025$521.0Mup 12.6%7 Aug 2025
31 Mar 2025$402.0Mup 10.5%1 May 2025
31 Dec 2024$559.2Mup 27.4%19 Feb 2025
30 Sep 2024$429.1Mup 9.8%30 Oct 2024
30 Jun 2024$462.7Mup 1.6%8 Aug 2024
31 Mar 2024$363.9Mdown 6.0%30 Apr 2024
31 Dec 2023$439.0Mup 11.1%21 Feb 2024
30 Sep 2023$390.8Mdown 19.9%2 Nov 2023
30 Jun 2023$455.6Mup 0.3%8 Aug 2023
31 Mar 2023$387.2Mdown 5.6%27 Apr 2023
31 Dec 2022$395.0Mdown 26.1%22 Feb 2023
30 Sep 2022$487.7Mdown 18.0%1 Nov 2022
30 Jun 2022$454.4Mdown 31.7%4 Aug 2022
31 Mar 2022$410.2Mdown 28.3%29 Apr 2022
31 Dec 2021$534.8Mdown 19.5%23 Feb 2022
30 Sep 2021$595.0Mdown 9.9%27 Oct 2021
30 Jun 2021$665.4Mdown 0.2%3 Aug 2021
31 Mar 2021$571.8Mdown 3.5%30 Apr 2021
31 Dec 2020$664.0Mdown 6.4%17 Feb 2021
30 Sep 2020$660.1Mup 2.9%28 Oct 2020
30 Jun 2020$666.7Mup 2.1%31 Jul 2020
31 Mar 2020$592.3Mup 8.9%1 May 2020
31 Dec 2019$709.2Mup 10.6%19 Feb 2020
30 Sep 2019$641.5Mup 8.9%25 Oct 2019
30 Jun 2019$653.2Mup 2.0%2 Aug 2019
31 Mar 2019$543.7Mup 1.2%2 May 2019
31 Dec 2018$641.2Mdown 1.8%19 Feb 2019
30 Sep 2018$589.0Mdown 4.5%6 Nov 2018
30 Jun 2018$640.4Mup 2.1%25 Jul 2018
31 Mar 2018$537.0Mup 2.7%27 Apr 2018
31 Dec 2017$652.7M—20 Feb 2018
30 Sep 2017$616.7M—27 Oct 2017
30 Jun 2017$627.5M—28 Jul 2017
31 Mar 2017$522.8M—1 May 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Zepbound revenue · Mounjaro revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · Rest of world revenue · China revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.